 | This articleneeds additional citations forverification. Please helpimprove this article byadding citations to reliable sources. Unsourced material may be challenged and removed. Find sources: "Aurobindo Pharma" – news ·newspapers ·books ·scholar ·JSTOR(February 2017) (Learn how and when to remove this message) |
 | |
| Company type | Public |
|---|---|
| NSE: AUROPHARMA BSE: 524804 | |
| Industry | Pharmaceuticals |
| Founded | 1986; 39 years ago (1986) |
| Founders | V. Ramprasad Reddy[1] K. Nityananda Reddy[1] |
| Headquarters | Hyderabad,Telangana, India |
| Products | |
| Revenue |  ₹29,002 crore (US$3.4 billion) (FY24)[3] |
| ₹5,843 crore (US$680 million) (FY24)[3] | |
| ₹3,173 crore (US$370 million) (FY24)[3] | |
| Total assets | ₹28,926 crore (US$3.4 billion) (2020)[4] |
| Total equity | ₹16,751 crore (US$2.0 billion) (2020)[4] |
Number of employees | 23,000[5] (2020) |
| Website | www |
Aurobindo Pharma Limited is an Indian multinationalpharmaceutical manufacturing company headquartered inHITEC City,Hyderabad. The company manufacturesgeneric pharmaceuticals andactive pharmaceutical ingredients. The company's area of activity includes six major therapeutic and product areas: antibiotics, anti-retrovirals, cardiovascular products, central nervous system products, gastroenterologicals, and anti-allergics.[6] The company markets these products in over 125 countries.[6] Its marketing partners includeAstraZeneca[7] andPfizer.[8]
The company commenced operations in 1988–89 with a single unit manufacturing semi-syntheticpenicillin (SSP) inPuducherry.[9] Aurobindo Pharma became a public company in 1992 and listed its shares in the Indian stock exchanges in 1995. Aurobindo Pharma also has a presence in key therapeutic segments such as neurosciences, cardiovascular, anti-retrovirals, anti-diabetics, gastroenterology and cephalosporins, among others.
Aurobindo Pharma features among the top 10 companies in India in terms of consolidated revenues.[6] Aurobindo exports to over 125 countries with more than 70% of its revenues derived out of international operations.
In 2014, Aurobindo purchased the generic operations ofActavis in 7 Western European countries for $41 million.[10][11]
Aurobindo Pharma plans to expand its product portfolio with high-value products inoncology,hormones,biosimilars and novel drug delivery solutions like depot injections, inhalers, patches and films. It has also set its sights on geographic expansion in new territories likePoland,Italy,Spain,Czech Republic,Portugal andFrance, as the generic drug market in these countries is relatively small.[12]
In 2017, Aurobindo Pharma inked a pact to acquire Portugal'sGeneris Farmaceutica SA from Magnum Capital Partners for a consideration of €135 million.[13] It also acquired four biosimilar products from Swiss firm TL Biopharmaceutical AG.[14]
Aurobindo Pharma Ltd. signed a definitive agreement to purchase the Apotex businesses in Poland, the Czech Republic, theNetherlands, Spain andBelgium. The agreement is conditional on the receipt of competition clearances for the transaction by the Dutch and Polish authorities. As part of the proposed sale, Apotex will enter into a transitional manufacturing and supply arrangement with Aurobindo to support the ongoing growth plans of these businesses.[15]
In May 2024, TheraNym Biologics, a wholly-owned subsidiary of Aurobindo Pharma Ltd signed a pact withMerck & Co. for expanding its biologics manufacturing facilities and exploring contract manufacturing operations for biologics.[16]
In December 2016, 20 Americanattorneys general filed a civil complaint accusing Aurobindo Pharma of a coordinated scheme to artificially maintain high prices for a generic antibiotic and diabetes drug. The complaint allegedprice collusion schemes between six pharmaceutical firms including informal gatherings, telephone calls, and text messages.[17]
On 11 April 2018, Aurobindo was featured in the Dutch documentary television programZembla.[18] It details accusations against the company of both environmental damage and poor working conditions for their employees inHyderabad, India.
On 20 June 2019, Aurobindo received a warning letter from theUSFDA after an inspection of its drug manufacturing facility, Aurobindo Pharma Limited inPydibhimavaram,Srikakulam District,Andhra Pradesh.[19] The warning letter summarized significant deviations fromcurrent good manufacturing practices (cGMP) foractive pharmaceutical ingredients (API).
On 7 October 2019, Aurobindo said it received seven observations from the USFDA for its unit-7 formulation plant in Telangana, with regard to potentially misleading documentation.[20] This caused its share prices to drop over 20%.[21]
In 2018,[22] and 2019,[23] Aurobindo Pharma USA recalled tablets containingvalsartan due to the detection ofN-Nitrosodiethylamine (NDEA) which is a probable human carcinogen.
In November 2019, Aurobindo Pharma USA recalled ranitidine tablets, capsules, and syrup due to the detection of unacceptable levels ofN-nitrosodimethylamine (NDMA).[24]
{{cite press release}}:|last= has generic name (help)Aurobindo Pharma USA, Inc. is conducting a voluntary recall of 80 lots of Amlodipine Valsartan Tablets USP, Valsartan HCTZ Tablets, USP and Valsartan Tablets USP to the consumer level due to the detection of trace amounts of an unexpected impurity found in the finished drug product. The impurity detected in the finished drug product is N-nitrosodiethylamine (NDEA), which is a substance that occurs naturally in certain foods, drinking water, air pollution, and industrial processes, and has been classified as a probable human carcinogen as per International Agency for Research on Cancer (IARC) classification.
This article incorporates text from this source, which is in thepublic domain.AurobindoPharma USA, Inc. and Acetris Health LLC. Are conducting a voluntary recall expansion of 39 lots of Valsartan and Amlodipine and Valsartan tablets to the consumer level due to the detection of trace amounts of an unexpected impurity found in the finished drug product. This recall is an expansion of the recall initiated 12/31/18 The impurity detected in the finished drug product is N-nitrosodiethylamine (NDEA), which is a substance that occurs naturally in certain foods, drinking water, air pollution, and industrial processes, and has been classified as a probable human carcinogen as per International Agency for Research on Cancer (IARC) classification.
This article incorporates text from this source, which is in thepublic domain.Aurobindo Pharma USA, Inc. is conducting a voluntary recall of 1 lot of Ranitidine Tablets 150mg to the retail level and 37 lots of Ranitidine Capsules 150mg, Ranitidine Capsules 300mg and Ranitidine Syrup 15mg/mL to the consumer level due to the detection of NDMA (Nitrosodimethylamine) Impurity in the finished product. The impurity detected is N-nitrosodimethylamine (NDMA), which is a substance that occurs naturally in certain foods, drinking water, air pollution, and industrial processes, and has been classified as a probable human carcinogen as per International Agency for Research on Cancer (IARC) classification.
This article incorporates text from this source, which is in thepublic domain.
